|
π
|
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
13 auth.
T. Hideshima,
D. Chauhan,
Y. Shima,
N. Raje,
F. Davies,
Y. Tai,
S. Treon,
B. Lin,
R. Schlossman,
P. Richardson,
...
G. Muller,
D. Stirling,
K. Anderson
|
9 |
2000 |
9
π
|
|
π
|
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
18 auth.
Deepak K. Gupta,
S. Treon,
Y. Shima,
T. Hideshima,
K. Podar,
Y. Tai,
B. Lin,
S. Lentzsch,
F. Davies,
D. Chauhan,
...
R. Schlossman,
P. Richardson,
P. Ralph,
Lei Wu,
F. Payvandi,
G. Muller,
D. Stirling,
K. Anderson
|
9 |
2001 |
9
π
|
|
π
|
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
16 auth.
D. Khanna,
Celia J. F. Lin,
D. Furst,
J. Goldin,
G. Kim,
M. Kuwana,
Y. Allanore,
M. Matucci-Cerinic,
O. Distler,
Y. Shima,
...
J. V. van Laar,
H. Spotswood,
Bridget Wagner,
J. Siegel,
A. Jahreis,
C. Denton
|
8 |
2020 |
8
π
|
|
π
|
Apoptosis-derived membrane vesicles drive the cGASβSTING pathway and enhance type I IFN production in systemic lupus erythematosus
15 auth.
Y. Kato,
Jeonghoon Park,
H. Takamatsu,
H. Konaka,
Wataru Aoki,
Syunsuke Aburaya,
M. Ueda,
Masayuki Nishide,
S. Koyama,
Yoshitomo Hayama,
...
Yuhei Kinehara,
T. Hirano,
Y. Shima,
M. Narazaki,
A. Kumanogoh
|
7 |
2018 |
7
π
|
|
π
|
CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications
13 auth.
S. Treon,
L. Pilarski,
A. Belch,
Abigail S. Kelliher,
F. Preffer,
Y. Shima,
C. Mitsiades,
N. Mitsiades,
A. Szczepek,
L. Ellman,
...
D. Harmon,
M. Grossbard,
K. Anderson
|
7 |
2002 |
7
π
|
|
π
|
Flavonoids such as Luteolin, Fisetin and Apigenin Are Inhibitors of Interleukin-4 and Interleukin-13 Production by ActivatedHuman Basophils
10 auth.
T. Hirano,
S. Higa,
J. Arimitsu,
T. Naka,
Y. Shima,
S. Ohshima,
...
M. Fujimoto,
T. Yamadori,
I. Kawase,
Toshio Tanaka
|
6 |
2004 |
6
π
|
|
π
|
A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus
11 auth.
Yoshiya Tanaka,
Kazuhiko Yamamoto,
T. Takeuchi,
N. Nishimoto,
N. Miyasaka,
T. Sumida,
...
Y. Shima,
K. Takada,
I. Matsumoto,
K. Saito,
T. Koike
|
6 |
2007 |
6
π
|
|
π
|
A case of BehΓ§etβs disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab
11 auth.
T. Hirano,
N. Ohguro,
S. Hohki,
K. Hagihara,
Y. Shima,
M. Narazaki,
...
A. Ogata,
K. Yoshizaki,
A. Kumanogoh,
T. Kishimoto,
Toshio Tanaka
|
6 |
2012 |
6
π
|
|
π
|
IL-18 gene polymorphisms affect IL-18 production capability by monocytes.
14 auth.
J. Arimitsu,
T. Hirano,
S. Higa,
M. Kawai,
T. Naka,
A. Ogata,
Y. Shima,
M. Fujimoto,
T. Yamadori,
Keisuke Hagiwara,
...
Tomoharu Ohgawara,
Y. Kuwabara,
I. Kawase,
Toshio Tanaka
|
6 |
2006 |
6
π
|
|
π¬
|
Therapeutic effect of tocilizumab on two patients with polymyositis.
M. Narazaki,
K. Hagihara,
Y. Shima,
A. Ogata,
T. Kishimoto,
Toshio Tanaka
|
6 |
2011 |
6
π¬
|
|
π
|
Proteomicsβbased identification of Ξ±βenolase as a tumor antigen in nonβsmall lung cancer
18 auth.
P. He,
T. Naka,
S. Serada,
M. Fujimoto,
Toshio Tanaka,
Shoji Hashimoto,
Y. Shima,
T. Yamadori,
Hidekazu Suzuki,
T. Hirashima,
...
K. Matsui,
H. Shiono,
M. Okumura,
T. Nishida,
I. Tachibana,
N. Norioka,
S. Norioka,
I. Kawase
|
6 |
2007 |
6
π
|
